Pharmacotherapeutic treatments are the most common intervention in the treatment of major depressive disorder (MDD). Response rates to the first antidepressant can be as low as 50-60%1 while clinically more meaningful remission rates are typically only between 20%2-35%1. Development of biological tests that would enable clinicians to select the correct class of antidepressant would significantly reduce morbidity and mortality associated with MDD by reducing the time to remission. We propose to evaluate potential biological tests that can predict remission from MDD when treated with a selective serotonin reuptake inhibitor (SSRI) and whether an individual patient is more likely to respond to a SSRI or a selective norepinephrine reuptake inhibitor (SNRI), the 2 most common classes of medication for MDD. We have shown that depressed patients have higher serotonin 1A (5-HT1A) binding potential than controls. Additionally, in a naturalistic treatment study we found MDD patients with higher 5-HT1A binding potential were less likely to remit to community based treatment. It has recently been shown that baseline serotonin transporter (5-HTT) availability in the midbrain, but not striatum3, predicts response to treatment with a SSRI.4 In our naturalistic study we show that remitters have higher 5-HTT binding potential in a regionally specific manner compared to non-remitters. The treatment protocol was not controlled in our pilot study and there were too few patients to determine if remission depended on the class of antidepressant. In this proposal, we propose to perform pretreatment positron emission tomography (PET) scans and have all patients receive a standardized treatment protocol of a SSRI followed by a SNRI in SSRI non-remitters. Escitalopram is the SSRI and desipramine the SNRI of choice because at the doses we will administer, they are highly selective for the respective transporters. We hypothesize that patients with high pre and postsynaptic 5-HT1A binding potential and low 5-HTT binding potential in the midbrain, amygdala, thalamus, and dorsal putamen will not remit to a SSRI and will remit to a SNRI. Finally, we will generate a predictive model of remission based on brain imaging outcome measures. Our overall goal is to reduce the trial and error associated with finding an effective antidepressant by using data from pre-treatment quantification of 5-HT1A receptors and 5-HTT to guide antidepressant treatment selection. ? ? ? ?

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-N (02))
Program Officer
Rumsey, Judith M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Pillai, Rajapillai L I; Zhang, Mengru; Yang, Jie et al. (2018) Will imaging individual raphe nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity? Depress Anxiety 35:411-420
Milak, Matthew S; Pantazatos, Spiro; Rashid, Rain et al. (2018) Higher 5-HT1A autoreceptor binding as an endophenotype for major depressive disorder identified in high risk offspring - A pilot study. Psychiatry Res Neuroimaging 276:15-23
Pillai, Rajapillai L I; Malhotra, Ashwin; Rupert, Deborah D et al. (2018) Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: A multimodal imaging study. Hum Brain Mapp 39:1043-1055
Iscan, Zafer; Rakesh, Gopalkumar; Rossano, Samantha et al. (2017) A positron emission tomography study of the serotonergic system in relation to anxiety in depression. Eur Neuropsychopharmacol 27:1011-1021
Kaufman, Joshua; DeLorenzo, Christine; Choudhury, Sunia et al. (2016) The 5-HT1A receptor in Major Depressive Disorder. Eur Neuropsychopharmacol 26:397-410
Oquendo, Maria A; Galfalvy, Hanga; Sullivan, Gregory M et al. (2016) Positron Emission Tomographic Imaging of the Serotonergic System and Prediction of Risk and Lethality of Future Suicidal Behavior. JAMA Psychiatry 73:1048-1055
Schneck, Noam; Miller, Jeffrey M; Delorenzo, Christine et al. (2016) Relationship of the serotonin transporter gene promoter polymorphism (5-HTTLPR) genotype and serotonin transporter binding to neural processing of negative emotional stimuli. J Affect Disord 190:494-498
Kaufman, Joshua; Sullivan, Gregory M; Yang, Jie et al. (2015) Quantification of the Serotonin 1A Receptor Using PET: Identification of a Potential Biomarker of Major Depression in Males. Neuropsychopharmacology 40:1692-9
Sullivan, Gregory M; Oquendo, Maria A; Milak, Matthew et al. (2015) Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder. JAMA Psychiatry 72:169-78
Olvet, Doreen M; Peruzzo, Denis; Thapa-Chhetry, Binod et al. (2014) A diffusion tensor imaging study of suicide attempters. J Psychiatr Res 51:60-67

Showing the most recent 10 out of 17 publications